Investigational drug · Phase 2
WVE-007
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight and Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "WVE-007"
First trial start
2025
Jan 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WVE-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight and Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "WVE-007" as an intervention, largest first.
- A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or ObesityPivotal-lookingRecruiting
Wave Life Sciences USA, Inc.Industry
NCT06842186 · 400 participants (planned) · Start Jan 31, 2025 · Primary completion Dec 2027
Drug: WVE-007 · For: Overweight and Obesity
Sites: Phoenix, Arizona; Baltimore, Maryland; Chisinau, Moldova · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight and Obesity
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- HDM1002Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight and Obesity
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- AZD9550Phase 23 trials
AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight
- TE-8105 MADPhase 22 trials
Immunwork, Inc. · Overweight and Obesity
- CPX101Phase 21 trial
Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. · Overweight and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.